Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 3/20 | 0.90 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.75 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.75 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.75 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.90 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.90 |
| ▸ | SRC | P12931 | 2/20 | 0.90 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.90 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.90 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.90 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.90 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.90 |
| ▸ | LDHA | P00338 | 1/20 | 0.90 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.90 |
| ▸ | FBP1 | P09467 | 1/20 | 0.90 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.90 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.90 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Phosphate SCHEMBL3828789 | 0.99 | P2RY1 (0.92) | P2RY1P2RY2SMN1; SMN2ADORA1SRC | |
| Vidarabine Phosphate SCHEMBL7111227 | 0.98 | P2RY1 (0.90) | P2RY1P2RY2SMN1; SMN2ADORA1SRC | |
| Adenosine Phosphate SCHEMBL27502312 | 0.96 | P2RY1 (0.98) | P2RY1P2RY2SMN1; SMN2ADORA1SRC | |
| Adenosine Phosphate SCHEMBL30012158 | 0.96 | P2RY1 (0.98) | P2RY1P2RY2SMN1; SMN2ADORA1SRC | |
| Adenosine Phosphate SCHEMBL3948645 | 0.96 | P2RY1 (0.98) | P2RY1P2RY2SMN1; SMN2ADORA1SRC | |
| Adenosine Phosphate SCHEMBL1338615 | 0.95 | P2RY1 (1.00) | P2RY1P2RY2SMN1; SMN2ADORA1SRC | |
| Adenosine Phosphate SCHEMBL19420134 | 0.95 | P2RY1 (1.00) | P2RY1P2RY2SMN1; SMN2ADORA1SRC | |
| Adenosine Phosphate SCHEMBL132458 | 0.95 | P2RY1 (1.00) | P2RY1P2RY2SMN1; SMN2ADORA1SRC | |
| Adenosine Phosphate SCHEMBL11977309 | 0.95 | P2RY1 (1.00) | P2RY1P2RY2SMN1; SMN2ADORA1SRC | |
| Adenosine Phosphate SCHEMBL13170051 | 0.95 | P2RY1 (1.00) | P2RY1P2RY2SMN1; SMN2ADORA1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108548782-A | The active detection method of 5'-NT and kinetics quantitative detection instrument | 易尚明天科技有限公司 | 2018-09-18 | — | — | CN | claimed |
| CN-103384830-A | Use of IDE as biomarker for scalp disorders | OREAL | 2013-11-06 | — | — | CN | claimed |
| US-20240218009-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240199680-A1 | SYNTHESIS OF FLUORINATED CYCLIC DINUCLEOTIDES | MERCK SHARP & DOHME LLC (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024119224-A1 | ELECTROCHEMICAL CELL AND USES THEREOF | AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2024-06-13 | — | — | WO | disclosed |
| US-20240182511-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2024-06-06 | — | — | US | disclosed |
| US-20230338344-A1 | AMPK Activators and Methods of Use Thereof | BIOVERATIV THERAPEUTICS INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4221700-A1 | AMPK ACTIVATORS AND METHODS OF USE THEREOF | Bioverativ Therapeutics Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| CN-116549865-A | Ceramic module emitting far infrared radiation and specific low dose ionizing radiation | A·C-T·魏 | 2023-08-08 | — | — | CN | disclosed |
| US-11702430-B2 | Aza-benzothiophene compounds as STING agonists | MERCK SHARP & DOHME LLC (US) | 2023-07-18 | — | — | US | disclosed |
| CN-116390925-A | AMPK activator | 卡尔优普公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-1999020396-A1 | METHODS AND APPARATUS FOR DETERMINING ANALYTES IN VARIOUS MATRICES | SAFETY ASSOCIATES, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| US-5780253-A | RAPID IDENTIFICATION OF ENZYME INHIBITORS TO PREVENT CONVERSION OF IONOSINE MONOPHOSPHATE TO ADENOSINE MONOPHOSPHATE AND GUANOSINE MONOPHOSPHATE | SANDOZ LTD. (CH) | 1998-07-14 | — | — | US | disclosed |
| US-5780254-A | Method for detection of herbicides | SANDOZ LTD (CH) | 1998-07-14 | — | — | US | disclosed |
| EP-0200056-B1 | METHOD AND KIT FOR DETECTING POLYRIBOADENOSINE SEGMENTS AND MESSENGER RNA | AlliedSignal Inc. (US) | 1992-12-23 | — | — | EP | disclosed |
| US-4950680-A | SYNERGISTIC ADMIXTURE OF A 1,4-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER, AND A PROSTACYCLIN | BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) | 1990-08-21 | — | — | US | disclosed |
| EP-0072581-A1 | The stabilization of working reagent solutions containing enzymes, and the use of such stabilized reagents in enzyme or substrate assays | American Monitor Corporation (US) | 1983-02-23 | — | — | EP | disclosed |
| US-4277562-A | Stabilized liquid enzyme and coenzyme compositions | MEDICAL ANALYSIS SYSTEMS, INC. | 1981-07-07 | — | — | US | disclosed |
| EP-0025351-A1 | Detection of bacteria in urine | DYNATECH AG (CH) | 1981-03-18 | — | — | EP | disclosed |
| EP-0009222-A2 | The stabilization of working reagent solutions containing NADH, NADPH, and/or enzymes, and the use of such stabilized reagents in enzyme or substrate assays | American Monitor Corp. (US) | 1980-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218009-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | STING1, IFNAR1, CGAS | ADORA1 260/4885ADORA3 493/4885ADORA2A 236/4885 |
| US-20230338344-A1 | AMPK Activators and Methods of Use Thereof | PRKAG2, PRKAG3, PRKAG1 | ADORA1 655/4885ADORA3 468/4885ADORA2A 203/4885 |
| US-11702430-B2 | Aza-benzothiophene compounds as STING agonists | STING1, IRF3, CGAS | ADORA1 74/4885ADORA3 96/4885ADORA2A 109/4885 |
| US-20240199680-A1 | SYNTHESIS OF FLUORINATED CYCLIC DINUCLEOTIDES | NT5C3B, DUT, NT5C2 | ADORA1 151/4885ADORA3 110/4885ADORA2A 52/4885 |
| US-20240182511-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | STING1, IFNAR1, CGAS | ADORA1 147/4885ADORA3 267/4885ADORA2A 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.